PMID- 34418562
OWN - NLM
STAT- MEDLINE
DCOM- 20220302
LR  - 20220311
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 172
DP  - 2021 Oct
TI  - SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and 
      mortality: A systematic review and meta-analysis of retrospective cohort studies.
PG  - 105836
LID - S1043-6618(21)00420-5 [pii]
LID - 10.1016/j.phrs.2021.105836 [doi]
AB  - Despite Sodium-glucose co-transporter-2 (SGLT2) inhibitors have been associated 
      with a reduced risk of heart failure in patients with type 2 diabetes mellitus 
      (T2DM), the effect observed for other cardiovascular (CV) and cerebrovascular 
      outcomes differed among clinical trials. Different observational studies have 
      investigated the effects of SGLT2 inhibitors on these outcomes and mortality. The 
      present meta-analysis aimed to assess the effects of SGLT2 inhibitors on the risk 
      of CV (major adverse CV event - MACE, non-fatal myocardial infarction, or 
      hospitalization for heart failure) and cerebrovascular (stroke) outcomes. A 
      systematic review was conducted in Pubmed from January 1, 2012 to November 31, 
      2020. Only retrospective cohort studies including as control group users of 
      dipeptidyl peptidase-4 (DPP-4) inhibitors or non-SGLT2 inhibitors were retained 
      and analysed separately. A random effect meta-analysis approach was used. This 
      study followed the PRISMA statement. Of the 158 references identified, 20 
      articles were selected for meta-analysis, of which 13 considered the comparison 
      with DPP-4 inhibitors and 7 the comparison with non-SGLT2 inhibitors. The pooled 
      intention-to-treat analysis showed a reduced risk of stroke with SGLT2 inhibitors 
      compared to DPP-4 inhibitors (Hazard ratio HR, 0.89; 95%CI, 0.82-0.96; I(2) 
      = 25%; p = 0.25) and non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91; I2 = 11%; 
      p = 0.34). Finally, SGLT2 inhibitors were also associated with a reduced risk of 
      CV outcomes and mortality in all comparisons. Our data support contemporary 
      society recommendations to prioritise the use of SGLT2 inhibitors in patients 
      with T2DM and at high risk for CV complications.
CI  - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Mascolo, Annamaria
AU  - Mascolo A
AD  - Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Naples, 
      Italy; Department of Experimental Medicine - Section of Pharmacology "L. 
      Donatelli", University of Campania "Luigi Vanvitelli", Naples, Italy. Electronic 
      address: annamaria.mascolo@unicampania.it.
FAU - Scavone, Cristina
AU  - Scavone C
AD  - Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Naples, 
      Italy; Department of Experimental Medicine - Section of Pharmacology "L. 
      Donatelli", University of Campania "Luigi Vanvitelli", Naples, Italy.
FAU - Scisciola, Lucia
AU  - Scisciola L
AD  - Department of Medical and Surgical Advanced Science, University of Campania 
      "Luigi Vanvitelli", Naples, Italy.
FAU - Chiodini, Paolo
AU  - Chiodini P
AD  - Medical Statistics Unit, University of Campania "Luigi Vanvitelli", Naples, 
      Italy.
FAU - Capuano, Annalisa
AU  - Capuano A
AD  - Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Naples, 
      Italy; Department of Experimental Medicine - Section of Pharmacology "L. 
      Donatelli", University of Campania "Luigi Vanvitelli", Naples, Italy.
FAU - Paolisso, Giuseppe
AU  - Paolisso G
AD  - Department of Medical and Surgical Advanced Science, University of Campania 
      "Luigi Vanvitelli", Naples, Italy; Mediterranea Cardiocentro, Naples, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210818
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
CIN - Pharmacol Res. 2021 Oct;172:105863. PMID: 34474101
CIN - Pharmacol Res. 2021 Oct;172:105862. PMID: 34481073
CIN - Pharmacol Res. 2021 Dec;174:105878. PMID: 34798269
MH  - Cardiovascular Diseases/mortality/*prevention & control
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Humans
MH  - Retrospective Studies
MH  - Risk
MH  - Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cardiovascular outcome
OT  - Cerebrovascular outcome
OT  - Mortality
OT  - Risk
OT  - SGLT2 inhibitors
OT  - Type 2 diabetes mellitus
EDAT- 2021/08/22 06:00
MHDA- 2022/03/03 06:00
CRDT- 2021/08/21 20:15
PHST- 2021/05/21 00:00 [received]
PHST- 2021/08/15 00:00 [revised]
PHST- 2021/08/16 00:00 [accepted]
PHST- 2021/08/22 06:00 [pubmed]
PHST- 2022/03/03 06:00 [medline]
PHST- 2021/08/21 20:15 [entrez]
AID - S1043-6618(21)00420-5 [pii]
AID - 10.1016/j.phrs.2021.105836 [doi]
PST - ppublish
SO  - Pharmacol Res. 2021 Oct;172:105836. doi: 10.1016/j.phrs.2021.105836. Epub 2021 
      Aug 18.